Immix Biopharma (IMMX) Reiterated at Market Outperform by Citizens on Interim Results for NEXICART-2 Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: IMMX) | Delayed: 7.97 +0.26 (3.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.71 | 52 Week High | $ | |||
| Open | $7.93 | 52 Week Low | $ | |||
| Day High | $8.16 | P/E | N/A | |||
| Day Low | $7.56 | EPS | $ | |||
| Volume | 1,249,716 | |||||
